This week, a delegation from Lilly is attending the 68th World Health Assembly (WHA) in Geneva. As the executive decision-making body of the World Health Organization, the WHA is comprised of government officials from Member States who oversee the organization’s policy and finances. Many are crucial partners for Lilly’s global health work, and the WHA presents a key platform for engaging with them and others.
Through activities this week, we are demonstrating how Lilly works hand-in-hand with governments, nongovernmental organizations, academia and others—through the Lilly NCD Partnership and Lilly MDR-TB Partnership—to address pressing health challenges. Our team is participating in sessions that highlight critical gaps as well as progress made against multidrug-resistant tuberculosis (MDR-TB) and noncommunicable diseases (NCDs).
We are not only sharing our work to develop innovative medicines but also how we strengthen healthcare systems to ensure safe access to those medicines in countries with the highest burdens of disease. It is also a chance to share the 2015 Global Health Programs Report, which describes the work Lilly and our nearly 50 partners have undertaken through the Lilly Global Health Programs.
There is a lot of optimism here about momentum on a number of health fronts including MDR-TB and NCDs. That momentum comes in part through partnership, and one goal this week is to help others understand how our collaborative work is making life better for millions across the world.